olanzapine + nizatidine

Adipogenic: The primary role of nizatidine in this combination is to mitigate the weight gain commonly observed with olanzapine treatment. Clinical studies show that the combination may have transient early effects in limiting weight gain at 3–4 weeks, but it does not significantly affect long-term weight control compared to placebo when continued for 12–16 weeks[1][2][3][4]. Neither drug in combination was found to adversely affect clinical outcomes in schizophrenia, and nizatidine was well-tolerated. **Olanzapine + nizatidine** is a combination of two pharmaceutical agents used in research to manage weight gain associated with olanzapine therapy, particularly in patients with schizophrenia. Olanzapine is an atypical antipsychotic that acts primarily as an antagonist at multiple neurotransmitter receptors in the brain, notably dopamine D2 and serotonin 5-HT2A receptors, while nizatidine is a histamine-2 (H2) receptor antagonist that reduces gastric acid secretion. The rationale for combining nizatidine with olanzapine was to investigate whether nizatidine could mitigate the weight gain commonly observed with olanzapine treatment. Clinical studies show that the combination may have transient early effects in limiting weight gain at 3–4 weeks, but it does not significantly affect long-term weight control compared to placebo when continued for 12–16 weeks[1][2][3][4]. Neither drug in combination was found to adversely affect clinical outcomes in schizophrenia, and nizatidine was well-tolerated.

Brand names

olanzapine + nizatidine

Other names

olanzapine + nizatidine